Abstracts Archive - Page 158 of 2607 - ACR Meeting Abstracts

Abstract Number: 0785 • ACR Convergence 2025
It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes
Chloe Heiting¹, Yiyuan Wu², Susan Goodman³, Peter Sculco⁴, Fei Wang², Rich Caruana⁵, Peter Cram⁶, Said Ibrahim⁷ and Bella Mehta⁸, ¹Northwell Health, New Hyde Park, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Thomas Jefferson University, Philadelphia, PA, ⁸Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Despite changing trends and increased utilization of total knee arthroplasty (TKA) in the United States,1 there are still prominent racial and ethnic disparities in…
Abstract Number: 0728 • ACR Convergence 2025
Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
Susana Romero-Yuste¹, Marta Domínguez-Álvaro², Antonio Fernández-Nebro³, Miquel Blasco⁴, Beatriz Ventosa⁵, Javier Narváez⁶, Gema Fernández⁷, Iñigo Rúa-Figueroa⁸, Desirée Luis-Rodríguez⁹ and Manuel Macía¹⁰, ¹University Hospital Complex of Pontevedra, Pontevedra, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ⁴Hospital clinic Barcelona, Barcelona Spain, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital la Paz, Madrid, Madrid, Spain, ⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁹Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain, ¹⁰Hospital Universitario Nuestra Señora de Candelaria,, Tenerife, Spain
Background/Purpose: ANCA-associated vasculitides (AAV)—granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and microscopic polyangiitis (MPA)are rare but severe systemic vasculitides with significant morbidity and…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 0870 • ACR Convergence 2025
Same Model, Different Results: Vendor and Microbiome Influence Reproducibility in Collagen Induced Arthritis
Brenda Seymour¹, Brendan Allen² and Kristine Kuhn³, ¹University of Colorado School of Medicine, Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: Although collagen-induced arthritis (CIA) in mice is a useful tool for studying inflammatory arthritis, it is a highly variable model with inconsistent disease severity…
Abstract Number: 0828 • ACR Convergence 2025
Two Common AI Models Create Poor Rheumatology Board Style Questions
Catherine Deffendall¹, Narender Annapureddy², Kevin Byram², Erin Chew² and Tyler Reese³, ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Madison, TN
Background/Purpose: Rheumatology fellows frequently prepare for board examinations using case-based, multiple-choice questions. However, there are few resources with enough questions to prepare and those currently…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 0792 • ACR Convergence 2025
Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases
Tania Chiha¹, Jiaqi Wang², Isha Jha³, Grace McMahon³, John Stone⁴ and Naomi Patel³, ¹Mount Auburn Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA

Background/Purpose: Glucocorticoids (GC) are used to treat various inflammatory and autoimmune diseases, though despite widespread use, real-world data on skin-specific GC toxicity are limited. To…
Abstract Number: 0878 • ACR Convergence 2025
Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
Maria Gabriella Raimondo¹, Hashem Mohammadian², Simon Rauber³, Stefano Alivernini⁴, Filippo Fagni⁵, Giulia Corte⁶, Koray Tascilar⁷, Alina Mihaela Ramming⁸, Juergen Rech², Maria Antonietta D´Agostino⁹, Georg Schett², Milena Pachowsky⁸, Arnd Kleyer¹⁰ and Andreas Ramming¹¹, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, ⁴Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁶- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Internal Medicine ³ – Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹¹Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Enthesitis is an early event in the course of psoriatic arthritis (PsA) and a hallmark feature of the disease. Currently, much of the understanding…
Abstract Number: 0822 • ACR Convergence 2025
Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
Kavya Sugur¹, Elizabeth Sloan², Emily Chong³, Sophia Matossian³, Katarina Kmetova⁴, Alyssa Rosek⁵, Christine Goudsmit⁶, Celine C. Berthier⁶, Pei-Suen Tsou³, Yu (Ray) Zuo³ and Jessica Turnier⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³University of Michigan, Ann arbor, MI, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ⁶University of Michigan, Ann Arbor, ⁷University of Michigan, Saline, MI
Background/Purpose: Most children with juvenile dermatomyositis (JDM) have chronic disease despite multi-drug immunosuppression, highlighting the need for targeted therapies. Neutrophil extracellular traps (NETs) are key…
Abstract Number: 0881 • ACR Convergence 2025
Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
Shu-Ju Lin¹, Kimberly Taylor², Shen Yang³, Qinwei Chen⁴, Shehani Alexander¹, Ye Cao⁵, Takanori Sasaki⁵, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin³ and Richard Ainsworth⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²UC San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific…
Abstract Number: 0880 • ACR Convergence 2025
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
Nicholas landini¹, lisa Jungblut², cecilia strappa³, Christian Blüthgen², Rucsandra Dobrota⁴, Muriel Elhai⁵, Carina Mihai⁶, Sinziana Muraru-Carbune², Martina Orlandi⁷, mariaelena Occhipinti⁸, Khadija El-Aoufy⁹, Gemma Lepri¹⁰, valeria panebianco¹¹, anna rita larici³, Anna-Maria Hoffmann-Vold¹², Cosimo Nardi¹³, Serena Guiducci¹⁴, Silvia Bellando-Randone¹⁵, Marco Matucci-Cerinic¹⁶, Thomas Frauenfelder², Oliver Distler¹⁷ and Cosimo Bruni¹⁸, ¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ³Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, rome, Italy, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁶University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ⁸Division of Radiology, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., pisa, Italy, ⁹Department of Health Science, University of Florence, Florence, Italy., firenze, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy., Rome, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. ², University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Florence, Italy, ¹⁴Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ¹⁵University of Florence, Florence, Florence, Italy, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁸University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc), especially in case of extensive disease detected on…
Abstract Number: 0885 • ACR Convergence 2025
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Grace Crossland¹, lennard Ostendorf², Vianey Chavez¹, Lindsay Mendyka¹, Deepak Rao³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death for young women, and over 75% of SLE patients experience skin manifestations – cutaneous…
Abstract Number: 0832 • ACR Convergence 2025
Elevated serum peptidylarginine deiminase 4 (PAD4) levels in anti-CCP antibody positive at-risk individuals with arthralgia who progress to rheumatoid arthritis.
Sana Sharrack¹, Xia Yu², Arun Jayaraman³, Laurence Duquenne⁴, Andrea Di Matteo⁵, Kate Harnden⁵, Lucy Thornton⁵, Helen Jayne-Sugden⁵, Jacqueline Nam⁶, Adam Smith⁵, Mia Collins⁷, Rachel Sparks³, Fanyi Jiang⁸, Kyriakos Konstantinidis⁹, Jessica Neisen¹⁰, Greet De Baets¹⁰, David Close¹¹, Chris chamberlain¹⁰, Adam Platt¹², Paul Emery¹³, Josie Meade² and Kulveer Mankia¹³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Sheffield, United Kingdom, ²Division of Oral Biology, School of Dentistry, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, ³AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gaithersburg, Maryland, United States of America, Gaithersburg, Maryland, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, United Kingdom, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Leeds, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁷AstraZeneca, Gothenburg, Sweden, ⁸AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Gothenburg, Sweden, Gothenburg, Sweden, ⁹AstraZeneca, R&I Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D,, Cambridge, United Kingdom, Cambridge, United Kingdom, ¹⁰AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Cambridge, United Kingdom, ¹¹AstraZeneca, Royston, United Kingdom, ¹²AstraZeneca, Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, Cambridge, United Kingdom, Melbourn, Royston,, United Kingdom, ¹³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies are one of the strongest risk factors for the development of rheumatoid arthritis (RA). Anti-CCP antibodies are generated against…
Abstract Number: 0888 • ACR Convergence 2025
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Adam S. Weinheimer¹, Olivia Pryor², Catalina Burbano³, Tyler Heath³, Livio Dukaj³, Shoshana M.K. Bloom³, Jackson Lirette³, Rachel Lent³, Prachi Dhanania³, Nicole A. Ladd³, Ryan Kritzer³, Hana Husic³, Shobitha Jillella³, Alexander Cristofaro², Chandan K. Pavuluri³, Jenna LaBelle³, Laurie Barefoot³, Shrikanta Chattopadhyay³, Andrew P. Ferretti³ and Cagan Gurer³, ¹TScan Therapeutics, Boston, MA, ²TScan Therapeutics, Waltham, ³TScan Therapeutics, Waltham, MA
Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].